tickrz reports
  
tickrz rank
C
Allergan plc (AGN)
Healthcare | Drugs - Generic
CEO: Brenton L. Saunders
Employees: 31200
allergan.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank221Dividend RankNOT AVAILABLE
Moat Rank139Financial Strength Rank183
Growth Rank3Momentum Rank355
DIVIDEND ANALYSIS
Dividend Yield0.32%
Payout Ratio4.23%
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio6.18x
P/B Ratio1.05x
P/S Ratio4.98x
EV/EBITDA Ratio39.44x
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity42%
Interest Coverage-3.4x
MOAT
ROE15.93%
ROIC-1.51%
Net Margin-6.46%
GROWTH
5 yr EPS Growth79.31%
5 yr SPS Growth26.02%
5 yr BPS Growth50.01%
Allergan plc 's strong growth translates to a Growth Rank in the top 25% of all stocks
 tickrz summary
Allergan plc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Allergan plc 's valuation score is comprised of a P/E ratio of 6.2x, a P/B ratio of 1.1x, a P/S ratio of 5x, and an EV/EBITDA ratio of 39.4x. Allergan plc ranks 221 out of the S&P 500 constituents on valuation--a relatively average score.Allergan plc ranks 42 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Allergan plc warrants further investigation.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Allergan plc appears to have a durable competitive advantage within the Healthcare sector. Allergan plc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -3.4x, a debt/equity ratio of 42% and a Moat Rank of 139 translate to an average Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 4.17% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 355. Based on its 12 month stock performance, Allergan plc will not appeal to momentum investors.

 yield
 value + yield
Unfortunately we do not have enough data to provide a dividend ranking for Allergan plc .

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 79.3% 5 year annualized EPS growth, 26% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 50% speak to its impressive growth ranking.

Allergan plc (AGN)
Healthcare | Drugs - Generic
CEO: Brenton L. Saunders
Employees: 31200
allergan.com


tickrz rank
C

VALUATION RATIOS
P/E Ratio6.18x
P/B Ratio1.05x
P/S Ratio4.98x
EV/EBITDA Ratio39.44x
DIVIDEND ANALYSIS
Dividend Yield0.32%
Payout Ratio4.23%
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity42%
Interest Coverage-3.4x
MOAT
ROE15.93%
ROIC-1.51%
Net Margin-6.46%
GROWTH
5 yr EPS Growth79.31%
5 yr SPS Growth26.02%
5 yr BPS Growth50.01%

TICKRZ RANK
Allergan plc receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Allergan plc 's valuation score is comprised of a P/E ratio of 6.2x, a P/B ratio of 1.1x, a P/S ratio of 5x, and an EV/EBITDA ratio of 39.4x. Allergan plc ranks 221 out of the S&P 500 constituents on valuation--a relatively average score.

WARREN BUFFETT RANKING
Allergan plc ranks 42 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Allergan plc warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Allergan plc appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Allergan plc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -3.4x, a debt/equity ratio of 42% and a Moat Rank of 139 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 4.17% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 355. Based on its 12 month stock performance, Allergan plc will not appeal to momentum investors.

VALUE + YIELD
Unfortunately we do not have enough data to provide a dividend ranking for Allergan plc .

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 79.3% 5 year annualized EPS growth, 26% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 50% speak to its impressive growth ranking.